Orkambi Study On Children Age 6-12 With DDF508: Cystic Fibrosis Treatment
Results are in from a 24-week study of Orkambi (lumacaftor/ivacaftor – a medication used in cystic fibrosis treatment) in 58 children with cystic fibrosis age 6-12 with two copies of the F508-delta mutation. Researchers were looking to examine the safety and efficacy of the CFTR potentiator on this age group and …
Lumacaftor/Ivacaftor longer trial on Heterozygous F508del Cystic Fibrosis Patients
At the end of November, the results of a clinical trial of Lumacaftor/Ivacaftor, also known as Orkambi, in CF patients with one F508Del mutation were published in the Annals of the American Thoracic Society. A past trial for Orkambi in this type of CF patient (heterozygous F508del) lasted 28 days …
13 year-old with Cystic Fibrosis is a Top Surfer in South Carolina
A thirteen-year-old with CF, Bree Labiak, is a top surfer in South Carolina. She competes with and sometimes wins over surfers ten or more years older than her. Read more about her here http://www.postandcourier.com/20160905/160909853/13-year-old-with-cystic-fibrosis-is-one-of-the-top-female-surfers-in-sc From the article: Dr. Patrick Flume, director of the Medical University of South Carolina Cystic Fibrosis …